Meet Vascular Perfusion.Solutions at ISHLT 2026

Toronto, Canada

April 22–25, 2026

Visit Vascular Perfusion.Solutions at ISHLT 2026

VP.S will be in Toronto to connect with the global transplant community advancing care for patients with advanced heart and lung disease.

At ISHLT 2026, we’ll be showcasing our flagship VP.S ENCORE®, a hypothermic machine perfusion device designed to extend cardiac graft preservation time through a simplified, effortlessly mobile approach.

Metro Toronto Convention Centre
April 22–25, 2026
Booth #: TBD

Attending ISHLT 2026? Let’s talk VP.S Encore®!

Meet with us during the conference or connect with us to learn more.

Simple. Portable. Reliable.

Portable Design

Portable Design

VP.S ENCORE® is a portable hypothermic oxygenated perfusion system designed to support extended cardiac graft preservation through a streamlined approach that reduces infrastructure and setup demands.

Hypothermic Preservation

Hypothermic Preservation

Weighing approximately 50 pounds, the compact system is intended for use during organ recovery and transport. It operates without blood or blood products, relying on FDA-approved perfusate with passive cooling.

Proven Preclinical Experience

Proven Preclinical Experience

More than 100 preclinical heart perfusions have been completed to date, with ongoing work conducted in collaboration with transplant surgeons and leading medical institutions.

FDA Breakthrough Device Program

VP.S ENCORE® is currently undergoing preclinical evaluation under FDA Breakthrough Device Designation.

About Vascular Perfusion.Solutions

Vascular Perfusion.Solutions is a Texas-based MedTech company focused on advancing cardiac graft preservation through simplified hypothermic machine perfusion technology.

The company takes a data-driven, evidence-based approach to research and development, working closely with leading scientists, engineers, and industry advisors to rigorously evaluate and refine its technology.

Its flagship system, VP.S ENCORE®, reflects this commitment to scientific integrity and practical innovation in cardiac transplantation.

Regulatory Note: VP.S ENCORE® is an investigational device, currently in development and not yet approved for commercial use by the FDA. Any features or descriptions shown are for informational purposes only.